Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients
Background/Aims The upper gastrointestinal (GI) toxicity associated with non‐steroidal anti‐inflammatory drugs (NSAID) use among cirrhotic patients remains unclear. The objective of this study was to evaluate the risk of upper GI adverse events associated with celecoxib and oral and parenteral non‐s...
Saved in:
Published in | Liver international Vol. 32; no. 5; pp. 859 - 866 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.05.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background/Aims
The upper gastrointestinal (GI) toxicity associated with non‐steroidal anti‐inflammatory drugs (NSAID) use among cirrhotic patients remains unclear. The objective of this study was to evaluate the risk of upper GI adverse events associated with celecoxib and oral and parenteral non‐selective NSAIDs in cirrhotic patients.
Methods
All the patients aged ≥ 20 years with a diagnosis of cirrhosis hospitalized for variceal bleeding and non‐variceal upper GI adverse events (oesophageal, gastric, duodenal ulcer, bleeding; gastritis and duodenitis) in 2006 were identified using ICD‐9‐CM diagnosis codes from inpatient claims from the Taiwan National Health Insurance Database. In the case‐crossover study design, the case period was defined as 1–30 days and the control period as 31–60 days before the date of hospitalization. The information for individual NSAID use was obtained from the outpatient pharmacy prescription database. Adjusted self‐matched odds ratios (OR) and their 95% confidence intervals (CI) were estimated with a conditional logistic regression model.
Results
A total of 4876 cirrhotic patients were included. The adjusted OR (95% CI) was 1.44 (0.89–2.31) for celecoxib, 1.87 (1.66–2.11) for oral non‐selective NSAIDs and 1.90 (1.55–2.32) for parenteral NSAIDs overall. Risks were similar for variceal and non‐variceal events. Concomitant use of proton pump inhibitors and histamine‐2 receptor antagonists tended to decrease the upper GI toxicity associated with non‐selective NSAIDs and celecoxib.
Conclusion
The use of nsNSAIDs but not celecoxib was associated with a two‐fold increased risk of variceal and non‐variceal upper GI events among cirrhotic patients. |
---|---|
Bibliography: | istex:F2FC8BE74B85CFE3584E88E05AB54353B7B230E2 ArticleID:LIV2739 ark:/67375/WNG-4Q0GMMG4-W Taiwan Department of Health - No. DOH098-TD-D-113-098016 Table S1. ICD-9-CM diagnostic codes used to identify cirrhotic patients with upper gastrointestinal adverse events and comorbid diseases.Table S2. Risk of variceal and non-variceal events associated with current use of celecoxib and non-selective NSAIDs in liver cirrhosis patients (N = 4,876).Table S3. Risks of upper gastrointestinal adverse events associated with NSAIDs use on different definition of case and control period among liver cirrhosis patients (N = 4,876). |
ISSN: | 1478-3223 1478-3231 |
DOI: | 10.1111/j.1478-3231.2011.02739.x |